

02-04-2009

FORM PTO-1595 (modified)

R



JET

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

103546638

To the Honorable Assistant Secretary and Commission

1. Name of conveying party(ies):

Kunio IWATANI

Additional name(s) of conveying party(ies) attached? NO

3. Nature of conveyance:

☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other ☐

Execution Date: October 30, 2008

2. Name and address of receiving party(ies):

(1) Name: OSAKA UNIVERSITYAddress: 1-1, Yamadaoka, Suita-shi, Osaka 565-0871, Japan(2) Name: KRINGLE PHARMA INC.Address: Senri Asahi Hankyu Bldg., 5-3,
Shinsenrihigashimachi 1-chome, Toyonaka-shi,
Osaka 560-0082, JapanAdditional name(s) & address(es) attached? NO

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _

A. Patent Application No.
12/226,447, filed October 17, 2008B. Patent No.(s)
, issuedAdditional numbers attached? NO

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: WENDEROTH, LIND & PONACK, L.L.P.
Attn: Warren M. Check, Esq.Street Address: 2033 K Street, N.W., Suite 800City: Washington, State: DC ZIP: 20006-10216. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41). \$40.00

☒ Enclosed (Check No. 89081)
Authorized to be charged to deposit account8. Deposit account number: 23-0975

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Warren M. Check, Reg. No. 33,367
Name of Person Signing

Signature

January 30, 2009
DateTotal number of pages including cover sheet: 3

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information:

Commissioner and Assistant Secretary of Patents and Trademarks
Box Assignments
Alexandria, VA 2231302/03/2009 MJAMA1 00000033 12226447
01 FC:0021 40.00 00

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and the Office of Management and Budget, Paperwork Reduction Project (0651-0011), Washington, D.C. 20503.

DOCKET NO. 2008_1803A

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

PATENT
REEL: 022213 FRAME: 0795

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration paid to each of the undersigned

Insert Name(s) of Inventor(s) Toshikazu NAKAMURA, Hiroshi FUNAKOSHI, Daisuke MIYAZAWA, Kunio IWATANI

the undersigned hereby sell(s) and assign(s) to

Insert Name(s) of Assignee(s) (1) OSAKA UNIVERSITY, (2) KRINGLE PHARMA INC.
Address of (1) 1-1, Yamadaoka, Suita-shi, Osaka 565-0871, Japan (2) Senri Asahi Hankyu Bldg., 5-3, Shinsenrihigashimachi 1-chome, Toyonaka-shi, Osaka 560-0082, Japan

Title of Invention (hereinafter designated as the Assignee) the entire right, title and interest for the United States as defined in 35 USC 100, in the invention known as

AGENT FOR TREATING POLYGLUTAMINE AGGREGATION-CAUSED DISEASE OR SUPPRESSING ONSET THEREOF

Date of Signing of Application for which an application for patent in the United States has been executed by the undersigned
on October 30, 2008

The undersigned agree(s) to execute all papers necessary in connection with this application and any continuing, divisional or reissue applications thereof and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

The undersigned agree(s) to execute all papers necessary in connection with any interference which may be declared concerning this application or continuation, division or reissue thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference.

The undersigned agree(s) to execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

The undersigned agree(s) to perform all affirmative acts which may be necessary to obtain a grant of a valid United States patent to the Assignee.

The undersigned hereby authorize(s) and request(s) the Commissioner of Patents to issue any and all Letters Patents of the United States resulting from said application or any division or divisions or continuing or reissue applications thereof to the said Assignee, as Assignee of the entire interest, and hereby covenants that he has (they have) full right to convey the entire interest herein assigned, and that he has (they have) not executed, and will not execute, any agreement in conflict herewith.


The undersigned hereby grant(s) the firm of WENDEROTH, LIND & PONACK, L.L.P., 2033 K Street, N.W., Suite 800, Washington, D.C. 20006-1021, the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent Office for recordation of this document.

In witness whereof, executed by the undersigned on the date(s) opposite the undersigned name(s).

Date _____, Name of the Inventor Toshikazu NAKAMURA


Date _____, Name of the Inventor Hiroshi FUNAKOSHI

Date _____, Name of the Inventor Daisuke MIYAZAWA

Date Oct. 30, 2008, Name of the Inventor 
Kunio IWATANI

(This assignment should preferably be acknowledged before a United States Consul. If not, then the execution by the Inventor(s) should be witnessed by at least two witnesses who sign here.)

Witness 

Witness 

The above application may be more particularly identified as follows:

U.S. Application Serial No. NEW Filing Date _____

Applicant Reference Number K12F2270(US) Atty Docket No. 2008 1803A

Title of Invention AGENT FOR TREATING POLYGLUTAMINE AGGREGATION-CAUSED DISEASE OR SUPPRESSING ONSET THEREOF